<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243450</url>
  </required_header>
  <id_info>
    <org_study_id>RAM-04</org_study_id>
    <nct_id>NCT01243450</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo</brief_title>
  <official_title>Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spear Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spear Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear
      Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acne Lesion Percent Reduction</measure>
    <time_frame>12 week</time_frame>
    <description>Reduction in number of Acne lesions by counting over 12 weeks</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">958</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Active generic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of acne for 12 weeks with generic tretinoin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment of acne for 12 weeks with Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of acne over 12 weeks with tretinoin Brand</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin</intervention_name>
    <description>Treatment of acne</description>
    <arm_group_label>Active generic</arm_group_label>
    <arm_group_label>Brand</arm_group_label>
    <other_name>active medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>treatment of acne</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A subject will be eligible to participate if they meet all of the following inclusion
        criteria:

          -  Normal, healthy male and female children and adults.

          -  Age 12 to 40 years.

          -  Written and verbal informed consent must be obtained. Subjects age 12 to 17
             (inclusive) must sign an assent for the study and a parent or a legal guardian must
             sign the informed consent (per FDA letter 8.21.07).

          -  Women of child-bearing potential must be non-pregnant and non-nursing, and must be
             willing to avoid pregnancy during the course of the study and during the menstrual
             cycle following completion of their participation in the study, adequate contraception
             is defined as regular use of any two of the following: oral, injectable
             contraceptives, condoms, spermicides, diaphragm, IUD, implantable and contraceptive
             patches. (oral contraceptives if used for at least three months and injectable
             contraceptives if used for at least 6 months)- prior to enrollment in the study, or
             abstinence.

          -  Have at least 20 inflammatory (papules and pustules) and 25 non-inflammatory (open and
             closed comedones) lesions with a maximum of 2 nodulocystic lesions on the face (per
             FDA letter 8.21.07).

          -  Global severity score from 2-4

          -  Able to refrain from the use of all other topical acne medications or antibiotics
             during the treatment period.

          -  Considered reliable and capable of understanding their responsibility and role in the
             study.

        Exclusion Criteria

        A subject will be eligible to participate if they meet none of the following exclusion
        criteria:

          -  Subjects with active cystic acne as evidenced by more than 2 facial nodules.

          -  More than 40 papules and/or pustules (inflammatory lesions)

          -  More than 60 open and or closed comedones/milia (non-inflammatory lesions)

          -  Overall severity grade of less than 2 or greater than 4,

          -  History of allergy or hypersensitivity to tretinoin.

          -  Significant history or clinical evidence of auto-immune, cardiovascular,
             gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease

          -  Use of systemic retinoid treatment within six months prior to study initiation.

          -  Oral contraceptives should not be started or changed within 3 months prior to study
             initiation or planned to change during the study.

          -  Pregnant or breast-feeding.

          -  Participation in a clinical study for acne within 4 months preceding study initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Cunningham, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cu-Tech</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cu-Tech, LLC</name>
      <address>
        <city>Mountain Lakes</city>
        <state>New Jersey</state>
        <zip>07046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <results_first_submitted>September 7, 2014</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Generic</title>
          <description>active cream
Tretinoin: Topical skin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo cream
Tretinoin: Topical skin
placebo</description>
        </group>
        <group group_id="P3">
          <title>Brand</title>
          <description>Tretinoin: Topical skin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="318"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="337"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>number of acne lesions by counting</population>
      <group_list>
        <group group_id="B1">
          <title>Active Generic</title>
          <description>Active generic group</description>
        </group>
        <group group_id="B2">
          <title>Brand</title>
          <description>Brand group</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="401"/>
            <count group_id="B2" value="404"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="940"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.2" spread="6.2"/>
                    <measurement group_id="B2" value="17.1" spread="6.1"/>
                    <measurement group_id="B3" value="17.6" spread="6.3"/>
                    <measurement group_id="B4" value="17.2" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acne Lesion Percent Reduction</title>
        <description>Reduction in number of Acne lesions by counting over 12 weeks</description>
        <time_frame>12 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Generic</title>
            <description>active cream
Tretinoin: Topical skin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo cream
Tretinoin: Topical skin
placebo</description>
          </group>
          <group group_id="O3">
            <title>Brand</title>
            <description>Tretinoin: Topical skin</description>
          </group>
        </group_list>
        <measure>
          <title>Acne Lesion Percent Reduction</title>
          <description>Reduction in number of Acne lesions by counting over 12 weeks</description>
          <units>percent reduction of number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.3" spread="10"/>
                    <measurement group_id="O2" value="-35" spread="8"/>
                    <measurement group_id="O3" value="-53.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Generic</title>
          <description>active cream
Tretinoin: Topical skin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo cream
Tretinoin: Topical skin
placebo</description>
        </group>
        <group group_id="E3">
          <title>Brand</title>
          <description>Tretinoin: Topical skin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>appendicitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William J. Cunningham, MD</name_or_title>
      <organization>Cu-Tech, LLC</organization>
      <phone>(973) 331-1620</phone>
      <email>wcunningham@cu-tech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

